CCL26, for example, has been shown to be highly expressed in recurrent hepatocellular carcinoma (HCC) (33), while CXCL2 is highly expressed in STK11-mutated NSCLC, which has a poorer response rate to ICIs (34). Here, CXCL2 is linked to non-small cell lung carcinoma.